A double-blind, placebo controlled, randomised, parallel group phase IIa study to investigate the efficacy, tolerability, and safety of different dosing regimens of AZD8848 administered intranasally to seasonal allergic rhinitis patients out of pollen season in a nasal allergen challenge model

Registry ID

EUCTR2010-020747-13

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

AstraZeneca AB

Start date

2010-07-16

Completion date

2012-02-10

Last update

2026-08-16

Conditions

• Allergic Rhinitis

Summary

Primary Objective: To compare the efficacy of 60 μg AZD8848 once weekly with 20 μg AZD8848 three (3) times weekly and with placebo when administered intranasally to seasonal allergic rhinitis patients out of season in a nasal allergen challenge model.

Locations

• , , Sweden

Related clinical trials

• Study of Yupingfeng Powder Treating Allergic Rhinitis (AR)
• Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice
• Facilitating Surgical Choice in Patient With Chronic Hypertrophic Rhinitis Using a Patient Decision Aid
• EmoTIChealth: Promoting Adolescent Health Through a Serious Game.
• Dietary Intervention on Atopy
• Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project

View on source registry